Sign inJoin waitlistJoin the waitlist

Eugene Pietzak

Assistant Attending Surgeon · New York Presbyterian Hospital

Credentials: · · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2026–2027
Urology
University of Pennsylvania Health System
2021–2026
Renaissance School of Medicine at Stony Brook University
2006–2010

Research

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Cell · 2018 · 695 citations
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
European Urology · 2017 · First of 18 authors · 299 citations
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Clinical Cancer Research · 2019 · 224 citations

BB
Bernard Bochner
43 papers
HA
Hikmat Al-Ahmadie
40 papers
David Solit
35 papers
GI
Gopa Iyer
35 papers
DB
Dean Bajorin
29 papers
EC
Eugene Cha
29 papers · 4 as a fellow
TD
Timothy Donahue
29 papers
GD
Guido Dalbagni
25 papers
JR
Jonathan Rosenberg
21 papers
AG
Alvin Goh
18 papers
SD
Sherri Donat
18 papers
JC
Jonathan Coleman
17 papers

Grants

Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer
National Cancer Institute · R37
Contact PI · $2M · Sloan-Kettering Inst Can Research
2022–2027

Clinical trials

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Principal investigator · Recruiting · Phase 3
Memorial Sloan Kettering Cancer Center
2025–2028
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2022–2027
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
Principal investigator · Active not recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2019–2027
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Study chair · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2028